Latest news with #Chien
Business Upturn
5 days ago
- Business
- Business Upturn
QPS Celebrates 30th Anniversary
Newark, Del., United States: QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalytics and clinical trials, is celebrating its 30-year anniversary in 2025. Founded by Dr. Benjamin Chien in 1995 to provide high-quality bioanalytical liquid chromatography with tandem mass spectrometry (LC-MS/MS) contract services, QPS is now recognized as a global leader in contract research. Over the past 30 years, the company has grown from a single office in Delaware, USA to a widely respected, global, full-service CRO with 8 locations spread across the US, EU, Asia, India and Australia, a clinical trial network of over 700 sites and an increased focus on leveraging the power of AI to accelerate clinical trials. This press release features multimedia. View the full release here: Dr. Benjamin Chien founder and CEO of QPS Holdings, LLC. Over the years, QPS has grown from a small molecule bioanalysis shop of three people to a global CRO with more than 1,200 employees. '30 years is a major milestone for QPS and I couldn't be more proud of the hard-working and innovative people who choose to work at QPS. They are the backbone of the company, and I am very grateful for their valuable contributions,' said founder and CEO of QPS, Dr. Benjamin Chien. 'Through QPS, the pharmaceutical and biotechnology industries have access to dedicated, focused scientific expertise across the drug development spectrum. In facilities around the world, QPS has assembled best-in-class instruments, platforms, people and processes required to conduct the studies necessary to support client drug discovery and development programs focused on obesity, type 2 diabetes, oncology, CNS diseases, cell and gene therapy, and more,' said Dr. Chien. Since its humble beginnings, QPS has expanded its service options, to include pharmacology, DMPK, toxicology, bioanalysis, translational medicine, leukopaks, PBMCs, cell therapy products, clinical trials, central lab services, and a full range of clinical research services. QPS is known for high-quality data, technical expertise, delivery of promised study timelines, collaborative solutions, and customer-focused strategies. Going forward, QPS plans to continue delivering custom-built research services that accelerate pharmaceutical breakthroughs across the globe. ABOUT QPS HOLDINGS, LLC QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, Asia and Australia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, leukopaks, PBMCs and cell therapy products, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit or email [email protected] . View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Yahoo
6 days ago
- Business
- Yahoo
QPS Celebrates 30th Anniversary
NEWARK, Del., June 04, 2025--(BUSINESS WIRE)--QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalytics and clinical trials, is celebrating its 30-year anniversary in 2025. Founded by Dr. Benjamin Chien in 1995 to provide high-quality bioanalytical liquid chromatography with tandem mass spectrometry (LC-MS/MS) contract services, QPS is now recognized as a global leader in contract research. Over the past 30 years, the company has grown from a single office in Delaware, USA to a widely respected, global, full-service CRO with 8 locations spread across the US, EU, Asia, India and Australia, a clinical trial network of over 700 sites and an increased focus on leveraging the power of AI to accelerate clinical trials. Over the years, QPS has grown from a small molecule bioanalysis shop of three people to a global CRO with more than 1,200 employees. "30 years is a major milestone for QPS and I couldn't be more proud of the hard-working and innovative people who choose to work at QPS. They are the backbone of the company, and I am very grateful for their valuable contributions," said founder and CEO of QPS, Dr. Benjamin Chien. "Through QPS, the pharmaceutical and biotechnology industries have access to dedicated, focused scientific expertise across the drug development spectrum. In facilities around the world, QPS has assembled best-in-class instruments, platforms, people and processes required to conduct the studies necessary to support client drug discovery and development programs focused on obesity, type 2 diabetes, oncology, CNS diseases, cell and gene therapy, and more," said Dr. Chien. Since its humble beginnings, QPS has expanded its service options, to include pharmacology, DMPK, toxicology, bioanalysis, translational medicine, leukopaks, PBMCs, cell therapy products, clinical trials, central lab services, and a full range of clinical research services. QPS is known for high-quality data, technical expertise, delivery of promised study timelines, collaborative solutions, and customer-focused strategies. Going forward, QPS plans to continue delivering custom-built research services that accelerate pharmaceutical breakthroughs across the globe. ABOUT QPS HOLDINGS, LLC QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, Asia and Australia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, leukopaks, PBMCs and cell therapy products, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit or email info@ View source version on Contacts QPS CONTACT: Name: Gabrielle PastorePhone: 1-302-635-4290Email: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
02-04-2025
- Business
- Forbes
Taiwan's UMC Opens $5 Billion Singapore Facility To Make AI, Automotive Chips
United Microelectronics' advanced chip manufacturing facility in Singapore. United Microelectronics Corp. (UMC) opened the first phase of its newly-built $5 billion advanced manufacturing facility in Singapore as the proliferation of artificial intelligence applications boosts demand for more complex chips. The facility in the eastern Singapore town of Pasir Ris can produce up to 30,000 wafers per month when full production starts in 2026, Hsinchu, Taiwan-based company said in a statement on Tuesday. It will boost UMC's total production capacity in Singapore by 47% to more than 1 million wafers annually, with room for further expansion, it added. 'This new state-of-the-art facility in Singapore signals a new phase of growth for UMC,' company president Shan-Chieh Chien said in the statement. 'It enhances our ability to meet future chip demand, driven by continuous innovations in connectivity, automotive and AI.' Singapore—a major chip manufacturing hub—has in recent years been attracting new investments from global semiconductor companies. Last year, Vanguard International Semiconductor partnered with Netherland's NXP Semiconductors to build a $7.8 billion wafer fabrication facility in the Lion City, while GlobalFoundries opened a $4 billion plant in 2023. UMC's new facility will be one of the most advanced semiconductor foundries in Singapore. The company said it will manufacture semiconductors for communications, automotive, and AI innovations. 'The unique geography of Singapore also makes the new facility well placed to support our customers in strengthening supply chain resilience,' Chien said. The expansion will create about 700 jobs locally over the next few years, including process and equipment engineers as well as research and development engineers, UMC said. 'This new fab introduces new leading edge specialty semiconductor capabilities and production capacity that will enhance Singapore's competitiveness as a critical node in the global semiconductor supply chain,' Jermaine Loy, Singapore Economic Development Board's managing director, said.
Yahoo
07-03-2025
- Health
- Yahoo
New surgical robot gives doctors 'superhuman' precision
What looks like a video game is some of the most delicate surgery a doctor can perform. 'It's really a race against the clock and it's very tight and complex anatomy as well,' said Doctor Victor Chien, a plastic surgeon at Cedars Sinani specializing in facial and neck reconstructive surgery, especially after cancer. He's demoing microsurgery to me – this is highly intricate surgery that typically involves blood vessels thinner than a human hair. 'This robot and the three-dimensional aspect of the visualization allows us to add efficiency add precision to these very difficult cases,' said Dr. Chien. Dr. Chien recently performed the first FDA robot-assisted microsurgery for head and neck cancer. The Symani Surgical System is remote-controlled. Doctors sit in a unique chair with hand controllers and use a 3D screen to guide the procedure. The system helps in two ways. First, it magnifies the area doctors are operating on, making delicate procedures easier to perform. It also reduces natural tremors in the hand. 'It's going to open up a whole new avenue of treatments for patients for diseases we never even considered treating,' said Dr. Curtis L. Cetrulo, director of the Division of Plastic Surgery at Cedars-Sinai. Cetrulo advocated for getting the system at the medical center and calls the first procedure a '100 percent success.' The system is currently approved for head and neck microsurgery, but it could expand to procedures inside the brain, abdomen, and chest in the future. 'These tools allow us to use our mastery in a level of precision and a level of dedication that was not previously possible,' concluded Chien. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
